3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
29
HER2-positive Breast Cancer
5
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Cyclophosphamide
18
fludarabine phosphate
12
pembrolizumab
11
Nivolumab
11
Brentuximab Vedotin
11
Mycophenolic Acid
10
Doxorubicin
10
fludarabine
9
Dacarbazine
9
Whole-Body Irradiation
8
Etoposide
8
Vinblastine
7
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Filgrastim
7
Cyclosporine
7
Granulocyte Colony-Stimulating Factor
6
Sirolimus
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Gemcitabine
5
Busulfan
5
Tacrolimus
4
pegfilgrastim
3
Vinorelbine
3
Stem Cell Transplantation
3
Rituximab
3
Radiation
3
Prednisone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
pertuzumab
×
90 days
×
Clear all
No trials found.